xemilofiban has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boersma, E; Brugts, JJ; Guarneri, M; Hu, S; Mercado, N; O'Neill, WW; Price, M; Schatz, R; Serruys, PW; Teirstein, P; Wijns, W | 1 |
| Tendera, M; Wojakowski, W | 1 |
1 review(s) available for xemilofiban and Coronary Artery Disease
| Article | Year |
|---|---|
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Stroke; Ticlopidine; Treatment Outcome | 2003 |
1 trial(s) available for xemilofiban and Coronary Artery Disease
| Article | Year |
|---|---|
Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial).
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Benzamidines; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Care; Risk Factors; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; United States | 2009 |